Menu Search
Equities

Femasys Inc

FEMY:NAQ

Femasys Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.15
  • Today's Change-0.02 / -1.71%
  • Shares traded90.55k
  • 1 Year change+256.81%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Femasys Inc's revenues fell -11.13% from 1.21m to 1.07m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 11.39m to a larger loss of 14.25m.
Gross margin65.67%
Net profit margin-1,756.83%
Operating margin-1,734.11%
Return on assets-96.51%
Return on equity-138.37%
Return on investment-108.58%
More ▼

Cash flow in USDView more

In 2023, Femasys Inc increased its cash reserves by 67.54%, or 8.75m. Cash Flow from Financing totalled 20.18m or 1,882.38% of revenues. In addition the company used 11.28m for operations while cash used for investing totalled 143.92k.
Cash flow per share-0.8116
Price/Cash flow per share--
Book value per share0.5060
Tangible book value per share0.504
More ▼

Balance sheet in USDView more

Femasys Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.83% of the market capitalization can be attributed to its 21.72m and debt could be paid in full if management chose.
Current ratio6.47
Quick ratio5.93
Total debt/total equity0.4229
Total debt/total capital0.2972
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.